Why Is Cancer Focused Monopar Therapeutics Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Monopar Therapeutics Inc (NASDAQ:MNPR) is presenting data from its ongoing Phase 1b trial of camsirubicin in patients with advanced soft tissue sarcoma at the CTOS Annual Meeting. The trial has enrolled 14 patients, with 9 showing stable disease after treatment. All patients in the fourth and fifth cohorts achieved stable disease, with some experiencing a ~20% tumor size reduction. No dose-limiting toxicity has been observed. The company's shares are up 50.90% at $0.65.
November 01, 2023 | 5:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Monopar Therapeutics' ongoing Phase 1b trial of camsirubicin shows promising results, leading to a 50.90% increase in the company's stock price.
The promising results from Monopar Therapeutics' ongoing Phase 1b trial of camsirubicin have likely led to increased investor confidence, resulting in a significant increase in the company's stock price. The fact that 9 out of 14 patients have shown stable disease after treatment, with some even experiencing a ~20% tumor size reduction, is a positive sign for the potential success of the drug. This could lead to increased revenues for the company in the future if the drug is approved and commercialized.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100